QIPP Committee Meeting
Analysis of Opioid Epidemic’s Impact on Health Care System and Treatment Availability

March 23, 2016
**Bill. No. 4056**

Passed unanimously and signed on March 14, 2016 by Governor Baker

Includes a number of recommendations from the Governor’s Opioid Working Group

<table>
<thead>
<tr>
<th>Key provisions relating to health care system</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mandatory evaluation of patients presenting with opioid overdose symptoms (effective July 1, 2016)</strong></td>
</tr>
<tr>
<td>• Must be conducted w/in 24 hrs of arrival at ED</td>
</tr>
<tr>
<td>• If treatment is indicated, must be offered (inpatient or outpatient)</td>
</tr>
<tr>
<td>• If patient refuses treatment, must be provided with information on outpatient resources</td>
</tr>
<tr>
<td>• Evaluation must be covered by all payers</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7-Day supply limit on opiate prescriptions (effective immediately)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• First time prescriptions to adults cannot exceed 7 day supply</td>
</tr>
<tr>
<td>• No prescription to minor can exceed 7 day supply</td>
</tr>
<tr>
<td>• Exceptions for emergencies, chronic pain, palliative care, oncology</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Partially filling prescriptions (effective immediately)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Pharmacist may partially fill schedule 2 drug at patient’s request, but may elect not to</td>
</tr>
<tr>
<td>• Unfilled portion of prescription is void</td>
</tr>
</tbody>
</table>
An Act relative to Substance Use, Treatment, Education and Prevention

Sections of particular relevance to the HPC

1. Requires the HPC, in consultation with DPH and DMH, to study and report on the availability of health care providers that serve patients with dual diagnoses of substance use disorder and mental illness, in inpatient and outpatient settings. The commission shall report to the joint committee on mental health and substance abuse and the house and senate committees on ways and means no later than 12 months following completion of the study.

2. Establishes a special commission to examine the feasibility of establishing a pain management access program, with the goal of increasing access to pain management for patients in need of comprehensive pain management resources. The executive director of the HPC shall serve on the commission. The commission shall begin meeting in June, 2016, and submit its recommendations along with drafts of any legislation by December 1, 2016.

3. Requires carriers to report to the Office of Patient Protection (OPP) on the total number of medical or surgical claims and mental health or substance use disorder claims submitted to and denied by the carrier.

4. Amends statute governing consumer appeal process for risk-bearing provider organizations (RBPOs) & accountable care organizations (ACOs) to require provider denials to inform patients of the right to appeal the decision to the OPP.
Primary aims of HPC’s analysis of the opioid epidemic in Massachusetts

1. Providing new research, data, or evidence to support and inform legislative action

2. Identifying & investing in strategic opportunities for care delivery/payment reforms for substance use disorder treatment that are likely to result in reduced spending and improved quality/access

3. Drawing on our experience with investment & technical assistance programs.
Key definitions and methods

To assess the impact of the opioid epidemic on the Massachusetts health care system, HPC examined the number of **opioid-related hospital visits**. For the purposes of this analysis opioid-related hospital visits includes ED visits, observation stays, and hospital admissions.

To assess the availability of medication-assisted treatment (MAT), an evidence-based protocol for individuals with opioid use disorder, the HPC examined the location, **geographic region**, and patient travel times for all three forms of MAT. For the purposes of this analysis, MAT includes outpatient methadone clinics, buprenorphine prescribers, and naltrexone providers.*

<table>
<thead>
<tr>
<th>Definitions</th>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hospital visits</strong></td>
<td>Inpatient admissions (47 percent of all visits in 2014), observation stays (5 percent), and emergency department visits (48 percent)</td>
</tr>
<tr>
<td></td>
<td>– Due to data limitations, only inpatient admissions and ED visits are included certain analyses. See “Sources” on slides for details.</td>
</tr>
<tr>
<td><strong>Opioid-related</strong></td>
<td>Hospital visits with a primary or secondary diagnosis related to abuse and misuse of prescription opioids and heroin**</td>
</tr>
<tr>
<td></td>
<td>– This set of diagnoses is broader than the set used in DPH’s previously published estimates of deaths averted</td>
</tr>
<tr>
<td></td>
<td>– See appendix for comparison of HPC &amp; DPH methodologies</td>
</tr>
<tr>
<td><strong>Geographic regions</strong></td>
<td>The HPC’s standard regions, described further in the 2015 Cost Trends Report.</td>
</tr>
</tbody>
</table>

* Methadone data as of 11/20/2015; Buprenorphine data as of 11/5/2015; Naltrexone data received on 8/20/2015

** Analysis based on AHRQ H-CUP methodology See appendix for comparison of codes
The number of opioid-related hospital visits have increased substantially since 2007.

Rate of Change of Opioid-Related Hospital Visits

<table>
<thead>
<tr>
<th>Years</th>
<th>Non-Heroin Opioids</th>
<th>Heroin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007-2008</td>
<td>6%</td>
<td>6%</td>
</tr>
<tr>
<td>2008-2009</td>
<td>15%</td>
<td>11%</td>
</tr>
<tr>
<td>2009-2010</td>
<td>6%</td>
<td>-29%</td>
</tr>
<tr>
<td>2010-2011</td>
<td>6%</td>
<td>52%</td>
</tr>
<tr>
<td>2011-2012</td>
<td>13%</td>
<td>23%</td>
</tr>
<tr>
<td>2012-2013</td>
<td>8%</td>
<td>35%</td>
</tr>
<tr>
<td>2013-2014</td>
<td>5%</td>
<td>43%</td>
</tr>
</tbody>
</table>

201% increase in heroin-related hospital visits between 2007 and 2014.

Source: HPC Analysis—CHIA, Hospital Inpatient Discharge Database, Outpatient Observation Database, and Emergency Department Database, 2007-2014.
The rate of opioid-related hospital visits varies significantly across HPC regions.

Note: Hot spots are defined as the communities containing the ten zip codes with the greatest rate of opioid-related inpatient admissions and a population greater than 1,000 residents.

Source: HPC Analysis—CHIA, Hospital Inpatient Discharge Database and Emergency Department Database, 2014; American Community Survey, 2009-2013.
The rate of opioid-related inpatient admissions varies by zip code with distinct hot spots in the Metro Boston area.

Darker shading indicates higher rates of admissions.

State and federal government is paying for most of opioid-related inpatient admissions

Graph 1:
Note: Principal Payer for Opioid-Related Inpatient Admissions, 2014, n=17,756
Source: HPC Analysis—CHIA, Hospital Inpatient Discharge Database, 2014
25-35 year old men are most at risk of an opioid-related inpatient admission. When adjusted for age and sex, residents of lower-income communities are more likely to experience an inpatient admission.

Inpatient Admissions by Gender
Opioid–related inpatient admissions per 100,000, 2014

Inpatient Admissions by Age
Opioid–related inpatient admissions per 100,000, 2014

Inpatient Admissions by Income Quartile
Adjusted for age and sex

Source: HPC Analysis—CHIA, Hospital Inpatient Discharge Database, 2014, American Community Survey, 2009-2013
Medication-assisted treatment (MAT) is an evidence-based protocol for individuals with opioid use disorder, but it is not widely accessible

Access to MAT reduces rates of addiction and infectious disease transmission and reduces inpatient admissions\(^1\)

Fewer than 50% of adults and adolescents with opioid addiction received MAT in 2012\(^2\)

Access to MAT varies widely - residents in some HPC regions must travel long distances to reach any type of MAT

Two out of the three types of MAT can be prescribed in any healthcare setting

Sources:
MAT availability varies widely by region, with no clear relationship to the burden of the epidemic

Sources:
- **Naltrexone**: Prescriber lists provided by Alkermes Pharmaceuticals (data received on 8/20/2015)
MAT availability varies significantly by drug type, leaving patients in some regions with limited access to certain treatment options.

Sources:
- **Naltrexone**: Prescriber lists provided by Alkermes Pharmaceuticals (data received on 8/20/2015)
Patients with opioid-related hospital visits often must travel more than 5 miles to access MAT

![Bar chart showing travel distances for different regions and treatment options.]

Note: Travel distances are defined as the distance between the patient’s zip code of residence and the zip code of the nearest in-state provider.

Sources:
- HPC analysis-CHIA Hospital Inpatient Discharge Database and Emergency Department Database, 2014
- **Naltrexone**: Prescriber lists provided by Alkermes Pharmaceuticals (data received on 8/20/2015)
Of the Commonwealth’s 15 regions, the Berkshires region has the highest rate of opioid-related hospital visits.

70% higher rate of opioid-related hospital visits than state average.

Comparatively long patient travel times for treatment:

- 33% of patients must travel more than 5 miles to a buprenorphine provider.
- 39% of patients must travel more than 5 miles to a methadone clinic.

No naltrexone providers.
Compared to the state average, Metro South has a 40% higher rate of opioid-related hospital visits and half the number of buprenorphine providers.
The Upper North Shore has the lowest availability of MAT, resulting in significant travel times for many patients

- Rate of opioid-related hospitals visits consistent with state average
- Low treatment availability across all forms of MAT
  - Fewest buprenorphine providers per capita among all regions
  - No methadone clinics
  - No naltrexone providers
- Comparatively long patient travel times for treatment
  - 31% of patients must travel more than 5 miles to a buprenorphine provider
Many CHART Phase 2 programs focus on interventions for patients with opioid dependence

**Berkshire Medical Center**

- **Suboxone Bridge Program** facilitates engagement with buprenorphine and enrollment in day treatment program upon discharge from detoxification hospital admission

**BID – Plymouth**

- Integrated social work within its ED to provide **assessment, crisis intervention, and follow-up** for patients presenting with SUD
- Partnership with **Clean Slate Centers** to provide outpatient **MAT** upon discharge from ED
- Collaboration with the **Plymouth Police Overdose OUTREACH** (Opioid User Taskforce to Reduce Epidemic And Care Humanely) Program to provide outreach and services to patients that have overdosed
- Partnership with the **Plymouth Drug and Mental Health Court** to provide jail pre-release interventions

**Hallmark Health**

- Interdisciplinary Collaborative Outreach and Adaptable Care at Hallmark Health (COACHH) team partnered with Melrose Fire/Rescue to receive **early notification of overdose patients**.
- Hallmark is developing a partnership with **DCF** to coordinate case management of **mothers of substance exposed newborns**.

---

1. This slide provides a sample of CHART initiatives focusing interventions for patients with opioid dependence and is not exhaustive.
Many CHART Phase 2 programs focus on interventions for patients with opioid dependence

Harrington Memorial Hospital

- Implemented an integrated care model in the ED to screen patients, coordinate with ED clinicians, and refer patients to treatment and social workers/care navigators in the community.
- Created a Partial Hospitalization Program to provide intensive services for patients with co-occurring substance abuse and mental health diagnoses.
- Partnership with Dudley District Court to provide clinical support and case management for patients with opioid related cases.

HealthAlliance Hospital

- HealthAlliance Hospital reengineered its ED workflow, including screening and engaging patients using SBIRT
- Health Integrated Collaborative Case Coordination (Hlc3) team. Hlc3Team initiates services immediately following discharge from the ED or hospital, including coordination across multiple partners and agencies, linkages to primary and behavioral care, and care planning

¹This slide provides a sample of CHART initiatives focusing interventions for patients with opioid dependence and is not exhaustive.
Neonatal Abstinence Syndrome (NAS)

Clinical diagnosis resulting from exposure to opioids in utero marked by low birth weight, respiratory distress, feeding difficulty, tremors, increased irritability and crying, diarrhea, and occasionally seizures.
Rate of NAS is increasing significantly in Massachusetts

From 2004 to 2013 the Incidence of NAS increased from <3/1000 hospital births to >16/1000 hospital births per year

Sources:
NAS is most frequently treated in higher cost settings in Massachusetts.
NAS discharge volume by hospital

Source: Massachusetts Health Data Consortium (MDHC) 2014 hospital data – Only includes hospitals with 12 or more NAS discharges
Neonatal Abstinence Syndrome (NAS) Investment Opportunity

$3,500,000

Eligible birthing hospitals

Summary

The NAS Investment Opportunity provides funding for inpatient and outpatient initiatives to eligible birthing hospitals in MA to develop and/or enhance evidence-based programs designed to improve care for infants with NAS and for women in treatment for opioid use disorder during and after pregnancy.

This model will provide additional funding for engagement and retention in treatment efforts, to be directly administered by DPH through an Interdepartmental Service Agreement (ISA). This expands a DPH led initiative that coordinates addiction services during pregnancy and for the first 6 months post-hospital discharge.

Objectives

1. **Identify emerging best practices** around inpatient treatment of and post-discharge follow-up on NAS;
   2. **Coordinate SUD treatment for mothers**; and
   3. **Extend the reach** of a federal grant awarded to DPH

   **Reduce LOS** associated with NAS by increasing adoption of best practices (e.g., breastfeeding, rooming-in protocols); **Reduce costs** while ensuring readmission rates also decline; and **Increase the use of best practices** across MA

Key Dates

- **Information Sessions:** March 25, 2016 (Webinar)
- **Proposals Due:** May 13, 2016
- **Anticipated Awardee Announcements:** July 2016
- **Anticipated Period of Performance:**
  - Category A: October 2016 to December 2017
  - Category B: October 2016 to December 2018
Joint HPC/DPH initiative allows for interventions to be applied across broader spectrum of continuum

HPC Pilot Program
Funded through FY16 State Budget
$500,000

DPH “Moms Do Care”
Program Funded through a federal grant
$3,000,000

HPC/DPH Expansion
Funded through CHART Investment Program to expand DPH's work
$3,000,000
HPC opioid abuse report – Next steps

HPC is issuing a report, including the preliminary data presented today, pursuant to chapter 258.

A draft report will be presented to this committee in an upcoming meeting.

Opioid Abuse Report includes

- Spotlight on: 1) availability of MAT and 2) dissemination of emerging and best practices regarding the treatment of NAS;
- Focused recommendations to further alleviate the opioid crisis in MA; and
- Compilation of all recommendations produced across the state to address the epidemic (e.g., Governor’s Opioid Working Group, Special Senate Committee on Opioid Addiction Prevention, Treatment, and Recovery Options, CHIA’s Access to SUD treatment report).
Contact Information

For more information about the Health Policy Commission:

Visit us: http://www.mass.gov/hpc

Follow us: @Mass_HPC

E-mail us: HPC-Info@state.ma.us
ICD-9-diagnosis codes used in HPC and DPH opioid-related hospital visit analyses

<table>
<thead>
<tr>
<th>ICD-9-CM diagnosis code</th>
<th>Description</th>
<th>HPC</th>
<th>DPH</th>
</tr>
</thead>
<tbody>
<tr>
<td>304</td>
<td>OPIOID DEPENDENCE-UNSPECIFIED</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>304.01</td>
<td>OPIOID DEPENDENCE-CONTINUOUS</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>304.02</td>
<td>OPIOID DEPENDENCE-EPISODIC</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>304.03</td>
<td>OPIOID DEPENDENCE, IN REMISSION</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>304.7</td>
<td>OPIOID OTHER DEP-UNSPECIFIED</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>304.71</td>
<td>OPIOID OTHER DEP-CONTINUOUS</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>304.72</td>
<td>OPIOID OTHER DEP-EPISODIC</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>304.73</td>
<td>OPIOID OTHER DEP-IN REMISSION</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>305.5</td>
<td>OPIOID ABUSE-UNSPECIFIED</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>305.51</td>
<td>OPIOID ABUSE-CONTINUOUS</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>305.52</td>
<td>OPIOID ABUSE-EPISODIC</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>305.53</td>
<td>OPIOID ABUSE-IN REMISSION</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>965</td>
<td>OPIUM POISONING</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>965.01</td>
<td>HEROIN POISONING</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>965.09</td>
<td>POISONING BY OTHER OPIATES AND RELATED NARCOTICS</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>E850.0</td>
<td>ACCIDENTAL POISONING BY HEROIN</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>E850.2</td>
<td>ACCIDENTAL POISONING BY OTHER OPIATES AND RELATED NARCOTICS</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>E935.0</td>
<td>ADVERSE EFFECTS OF HEROIN</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>E935.2</td>
<td>OTHER OPIATES AND RELATED NARCOTICS CAUSING ADVERSE EFFECTS IN THERAPEUTIC USE</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

Note: HPC’s methodology is adapted from a method developed by AHRQ (http://www.ncbi.nlm.nih.gov/books/NBK246983/), but adds diagnoses related to heroin.